| 1-ethyl-3-(6-methylphenanthridine-8-il) urea modulates TLR3/9 activation and induces selective pro-inflammatory cytokine expression in vitro NK Teofilović, M Bihi, MR Stojković, LM Tumir, K Ester, M Kralj, D Majhen, ... Bioorganic & medicinal chemistry letters 27 (7), 1530-1537, 2017 | 4 | 2017 |
| 1070 HexaBody-CD27 enhances T-cell activation, proliferation, cytokine secretion and cytotoxic activity independently of Fc gamma receptor-mediated crosslinking K Nürmberger, A Imle, A Toker, K Strumane, S Fellermeier-Kopf, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 575 SPECIFIC IN VIVO DELIVERY OF PROCOLLAGEN a1 (I) siRNA IN LIPID-LIKE CARRIERS INHIBITS THE PROGRESSION OF BILIARY LIVER FIBROSIS C Calvente, M Diken, A Sehgal, YO Kim, D Schuppan Journal of Hepatology, S236, 2013 | 1 | 2013 |
| A COLLAGEN-TARGETED NEAR INFRARED SPECTROSCOPY AND POSITRON EMISSION TOMOGRAPHY CONTRAST AGENT FOR LIVER FIBROSIS IMAGING YO Kim, S Gorres, M Diken, S Pektor, N Bausbacher, KS Park, Y Popov, ... HEPATOLOGY 70, 85A-85A, 2019 | | 2019 |
| A complex epigenome-splicing crosstalk governs epithelial-to-mesenchymal transition in metastasis and brain development SK Sahu, E Agirre, M Inayatullah, A Mahesh, N Tiwari, DP Lavin, A Singh, ... Nature Cell Biology 24 (8), 1265-1277, 2022 | 18 | 2022 |
| A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma RA Jabulowsky, C Loquai, E Derhovanessian, H Mitzel-Rink, J Utikal, ... Annals of Oncology 29, viii439, 2018 | 15 | 2018 |
| A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy L Heesen, R Jabulowsky, C Loquai, J Utikal, C Gebhardt, J Hassel, ... Annals of Oncology 28, xi14-xi15, 2017 | 8 | 2017 |
| A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice N Salomon, F Vascotto, A Selmi, M Vormehr, J Quinkhardt, T Bukur, ... Oncoimmunology 9 (1), 1771925, 2020 | 39 | 2020 |
| A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo M Vormehr, K Reinhard, R Blatnik, K Josef, JD Beck, N Salomon, ... Oncoimmunology 8 (3), 1553478, 2019 | 18 | 2019 |
| A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis C Krienke, L Kolb, E Diken, M Streuber, S Kirchhoff, T Bukur, ... Science 371 (6525), 145-153, 2021 | 330 | 2021 |
| A novel TLR agonist as a potent anti-cancer therapeutic agent J Petschenka, F Vascotto, KC Walzer, R Roth, A Koenig, C Ettingshausen, ... EUROPEAN JOURNAL OF IMMUNOLOGY 47, 11-11, 2017 | | 2017 |
| Abstract A004: Systemic RNA vaccines: Connecting effective cancer immunotherapy with antiviral defense mechanisms LM Kranz, M Diken, H Haas, S Kreiter, C Loquai, KC Reuter, M Meng, ... Cancer Immunology Research 4 (11_Supplement), A004-A004, 2016 | | 2016 |
| Abstract A110: Mutant MHC class II epitopes drive therapeutic immune responses to cancer M Vormehr, S Kreiter, N Roemer, M Diken, M Löwer, F Vascotto, ... Cancer Immunology Research 4 (1_Supplement), A110-A110, 2016 | 2 | 2016 |
| Abstract B040: Oncolytic measles virus for tumor vaccination S Hutzler, S Erbar, RA Jabulowsky, T Beissert, J Hanauer, O Tuereci, ... Cancer Immunology Research 4 (1_Supplement), B040-B040, 2016 | | 2016 |
| Abstract B041: A novel nanoparticular formulated tetravalent RNA cancer vaccine for treatment of patients with malignant melanoma RA Jabulowsky, C Loquai, M Diken, LM Kranz, H Haas, S Attig, CM Britten, ... Cancer Immunology Research 4 (1_Supplement), B041-B041, 2016 | 3 | 2016 |
| Abstract B62: Evaluation of systemic RNA-based cancer vaccine induced T-cell responses via mouse T-cell receptor (TCR) profiling LM Kranz, B Schrörs, T Bukur, C Albrecht, L Leppin, M Suchan, M Faryna, ... Cancer Immunology Research 8 (4_Supplement), B62-B62, 2020 | | 2020 |
| Abstract CT020: MERIT: Introducing individualized cancer vaccines for the treatment of TNBC-a phase I trial S Heesch, V Bukur, J Buck, J Diekmann, M Diken, K Ewen, H Haas, ... Cancer Research 76 (14_Supplement), CT020-CT020, 2016 | 3 | 2016 |
| Abstract CT032: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma RA Jabulowsky, C Loquai, M Diken, LM Kranz, H Haas, S Attig, N Bidmon, ... Cancer Research 76 (14_Supplement), CT032-CT032, 2016 | 7 | 2016 |
| Abstract CT034: a first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent melanoma immunotherapy RA Jabulowsky, C Loquai, J Utikal, J Hassel, R Kaufmann, ... Cancer Research 77 (13_Supplement), CT034-CT034, 2017 | 4 | 2017 |
| Abstract CT201: The Mutanome Engineered RNA Immuno-Therapy (MERIT) project S Heesch, CM Britten, V Bukur, J Buck, J Castle, J Diekmann, M Diken, ... Cancer Research 75 (15_Supplement), CT201-CT201, 2015 | 2 | 2015 |
